Sorafenib

For research use only. Not for use in humans.

製品コードS7397 別名：BAY 43-9006

分子量(MW)：464.82

Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.

サイズ

価格(税別)

在庫

20mg	JPY 26400	あり
50mg	JPY 46800	あり
200mg	JPY 113200	あり

最寄りの販売代理店を探す

東京
北海道
東北
北関東
南関東
東海
北信越
近畿
中国
四国
九州

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください：[email protected]

バルク問合せ

代表番号: 03-5615-9297 | 電子メール：[email protected]

文献中Selleckの製品使用例(206)

製品安全説明書

Raf阻害剤の選択性比較

生物活性

製品説明

Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.

ターゲット

Raf-1 ^[1] (Cell-free assay)	mVEGFR2(Flk1) ^[1] (Cell-free assay)	mVEGFR3 ^[1] (Cell-free assay)	B-Raf ^[1] (Cell-free assay)	B-Raf (V599E) ^[1] (Cell-free assay)	もっとクリックする
6 nM	15 nM	20 nM	22 nM	38 nM	もっとクリックする

体外試験

Sorafenib inhibits both wild-type and V599E mutant B-Raf activity with IC50 of 22 nM and 38 nM, respectively. Sorafenib also potently inhibits mVEGFR2 (Flk-1), mVEGFR3, mPDGFRβ, Flt3, and c-Kit with IC50 of 15 nM, 20 nM, 57 nM, 58 nM, and 68 nM, respectively. Sorafenib weakly inhibits FGFR-1 with IC50 of 580 nM. Sorafenib tosylate is not active against ERK-1, MEK-1, EGFR, HER-2, IGFR-1, c-Met, PKB, PKA, cdk1/cyclinB, PKCα, PKCγ, and pim-1. Sorafenib markedly inhibits VEGFR2 phosphorylation in NIH 3T3 cells with IC50 of 30 nM, and Flt-3 phosphorylation in HEK-293 cells with IC50 of 20 nM. Sorafenib potently blocks MEK 1/2 and ERK 1/2 phosphorylation in most cell lines but not in A549 or H460 cells, while having no effect on inhibition of the PKB pathway. Sorafenib inhibits the proliferation of HAoSMC and MDA-MB-231 cells with IC50 of 0.28 μM and 2.6 μM, respectively. ^[1] In addition to inhibition of the RAF/MEK/ERK signaling pathway, Sorafenib significantly inhibits the phosphorylation of eIF4E and down-regulates Mcl-1 levels in hepatocellular carcinoma (HCC) cells in a MEK/ERK-independent manner. Sorafenib inhibits the proliferation of PLC/PRF/5 and HepG2 cells with IC50 of 6.3 μM and 4.5 μM, respectively, and leads to the significant induction of apoptosis. ^[2]

細胞データ

Cell Lines	Assay Type	Activity Description	PMID
MV-4-11	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2Xwc2lEPTB;MD6wNFAxODNyMzFOwG0>	NVHaNWV3W0GQR1XS
MONO-MAC-6	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUfJR\|UxRTBwMEC0NVgh\|ryP	M1fITXNCVkeHUh?=
ALL-PO	M2PH[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlfVTWM2OD1yLkCzNVg1KM7:TR?=	NIrGdlFUSU6JRWK=
NKM-1	M1TN[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NE\JfXJKSzVyPUCuNFc1OTZizszN	NVq0SXRXW0GQR1XS
CGTH-W-1	NXHydY5YT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEjZXYlKSzVyPUCuNlUxOjJizszN	MlPTV2FPT0WU
BB65-RCC	M4HGXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M373OWlEPTB;MD60O\|A4OyEQvF2=	NEX5TZVUSU6JRWK=
NOS-1	NHzFVWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1r2ZmlEPTB;MD61OlM3KM7:TR?=	NVH3cWc3W0GQR1XS
SH-4	M4Tjbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4jLdGlEPTB;MD62OVYyOyEQvF2=	NVXlOHJPW0GQR1XS
HOP-62	M1XxPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkPmTWM2OD1yLki1NFg5KM7:TR?=	MmjoV2FPT0WU
HCC2998	M13L[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoPHTWM2OD1yLki4PFE5KM7:TR?=	MYjTRW5ITVJ?
GDM-1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX;UblhWUUN3ME2wMlkxPjl6IN88US=>	NU\QTVFYW0GQR1XS
KM12	NWTCbGM{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4XyPWlEPTB;MT6wNlA6QCEQvF2=	MX3TRW5ITVJ?
LB2518-MEL	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1zOemlEPTB;MT6yNFgxQSEQvF2=	NYf2eZJPW0GQR1XS
NCI-H1436	NGDhNYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkfSTWM2OD1zLkKxOlc5KM7:TR?=	NEC1fnBUSU6JRWK=
EM-2	M3jY[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkXoTWM2OD1zLkO1OVc5KM7:TR?=	M2rISnNCVkeHUh?=
LAMA-84	NEKwfG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3jGR2lEPTB;MT6zO\|Y1QCEQvF2=	NG\MVpJUSU6JRWK=
KG-1	Mkn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MofITWM2OD1zLkS3PVM2KM7:TR?=	M3LwVHNCVkeHUh?=
A388	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYTJR\|UxRTFwNUmxOlUh\|ryP	NGPVU4ZUSU6JRWK=
no-10	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1L3TmlEPTB;MT62NVczPiEQvF2=	NYDr[YdwW0GQR1XS
SF126	MnvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4j4[2lEPTB;MT62N\|gyOiEQvF2=	NGjWSWpUSU6JRWK=
MEG-01	Mnu5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnzjTWM2OD1zLkiwPVgh\|ryP	NXzIN4RWW0GQR1XS
A3-KAW	NYrDVFlFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX:3eI46UUN3ME2xMlg5PDJizszN	NYXMSnJ[W0GQR1XS
D-247MG	M4DNV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo\4TWM2OD1{LkG0OFgh\|ryP	NXHSfFc6W0GQR1XS
OVCAR-4	NHvxOppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEnvV5NKSzVyPUKuNlE{QTNizszN	MUTTRW5ITVJ?
NCI-SNU-1	NVHZdIs2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmnTTWM2OD1{LkOxOlIh\|ryP	Ml36V2FPT0WU
NCI-H2171	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnnHTWM2OD1{LkO5O\|Y1KM7:TR?=	NGPueJZUSU6JRWK=
SIG-M5	NYnycnFVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{DWZ2lEPTB;Mj60NlI1OiEQvF2=	MmPoV2FPT0WU
BE-13	M2Lj[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MY\JR\|UxRTJwNkm2NFkh\|ryP	NEPiO4VUSU6JRWK=
K052	MoewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MorBTWM2OD1{Lke0OlE3KM7:TR?=	NIPwRWFUSU6JRWK=
L-540	M3HWWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1i3eWlEPTB;Mj63OVc5QSEQvF2=	MoXJV2FPT0WU
KMOE-2	NXzud5Y4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2rqbGlEPTB;Mj64NVM2KM7:TR?=	MV\TRW5ITVJ?
MFH-ino	NIrFU2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn3BTWM2OD1{LkmyNVg2KM7:TR?=	NWLTOFZEW0GQR1XS
HL-60	NEnaeW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYrJR\|UxRTNwME[yPVkh\|ryP	M3nDTXNCVkeHUh?=
HCC2218	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXHJR\|UxRTNwMUKwNFMh\|ryP	Mmr1V2FPT0WU
TE-5	M1L0dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{n6NGlEPTB;Mz6xN\|E3OiEQvF2=	MnTjV2FPT0WU
MZ1-PC	NF3Fd2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2q4U2lEPTB;Mz60O\|UxQSEQvF2=	NH3GW3VUSU6JRWK=
MRK-nu-1	MmH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF7TfYJKSzVyPUOuOlE1PjhizszN	M3vGV3NCVkeHUh?=
MZ7-mel	NUT5R4NST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX\3TI9WUUN3ME2zMlY3ODl7IN88US=>	NWDHco42W0GQR1XS
BC-1	M3rSV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVP2RYpGUUN3ME2zMlc1ODJizszN	NGnFNWlUSU6JRWK=
ST486	M{jTTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoToTWM2OD1\|LkizOlc{KM7:TR?=	M4i3VHNCVkeHUh?=
KS-1	M3rDUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3viZWlEPTB;Mz64PFE6QCEQvF2=	M2WySXNCVkeHUh?=
SK-NEP-1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEPmTFZKSzVyPUSuNVY5OTVizszN	MkSyV2FPT0WU
BC-3	NInjeGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIXaTmZKSzVyPUSuNlM{QTFizszN	NGLNRphUSU6JRWK=
NCI-H1581	M1nFNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4KyS2lEPTB;ND6yPFc6QCEQvF2=	M1T0NXNCVkeHUh?=
MHH-PREB-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYDJR\|UxRTRwNEC0PFQh\|ryP	MWjTRW5ITVJ?
NOMO-1	M{XRWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGezdW9KSzVyPUSuOFg6ODVizszN	NFT5dYpUSU6JRWK=
QIMR-WIL	NUTmc4h4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYPJR\|UxRTVwMEeyPVQh\|ryP	M37pcXNCVkeHUh?=
SF539	NHnXNFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1f5cmlEPTB;NT6xN\|IzPyEQvF2=	NE[zc5FUSU6JRWK=
TE-12	MmPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYDJR\|UxRTVwMkS5Nlkh\|ryP	NV:4SYJ7W0GQR1XS
NCI-H510A	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFXQVpVKSzVyPUWuOFE3QDVizszN	MnX4V2FPT0WU
JAR	M2rRWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M16xUWlEPTB;NT61NFgzPCEQvF2=	NFjoZmtUSU6JRWK=
no-11	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEfCZnpKSzVyPUWuO\|M2PjhizszN	NYPaPFUyW0GQR1XS
BV-173	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWfJR\|UxRTVwOUW2PFIh\|ryP	MV\TRW5ITVJ?
SR	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUTydJFEUUN3ME22MlAxPjd6IN88US=>	NGq0RWlUSU6JRWK=
MOLT-16	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3[3dGlEPTB;Nj6yOVI3PiEQvF2=	MYXTRW5ITVJ?
MZ2-MEL	M3njN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlHsTWM2OD14LkOxPFM6KM7:TR?=	M2myeXNCVkeHUh?=
SW954	NU\DO3ZIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEDmNmJKSzVyPU[uOFU5PjZizszN	NUjSdXZZW0GQR1XS
ML-2	Mm\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2mzSGlEPTB;Nj61Nlg1QSEQvF2=	MkHFV2FPT0WU
OCI-AML2	M4\rN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4O2W2lEPTB;Nj62NVA3OiEQvF2=	MkHFV2FPT0WU
SIMA	NYXBPG55T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIrrOHRKSzVyPUeuNFAyODFizszN	M3TRVHNCVkeHUh?=
DOHH-2	NHu2XY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlrRTWM2OD15LkC1Olc3KM7:TR?=	NIC2RZRUSU6JRWK=
697	NILHd2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkTWTWM2OD15LkC1PVg6KM7:TR?=	MYTTRW5ITVJ?
NB1	NUjRPHY4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYjIfJA{UUN3ME23MlQxPDB5IN88US=>	MUfTRW5ITVJ?
D-392MG	NX;Jbop2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVvJR\|UxRTdwNkK2OlMh\|ryP	NGixS3dUSU6JRWK=
ES8	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4n2S2lEPTB;Nz63OlUxOyEQvF2=	Mo[zV2FPT0WU
RPMI-8226	NF7PUIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkDVTWM2OD15Lki0OVEyKM7:TR?=	MX\TRW5ITVJ?
IST-MEL1	MoLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{LuSWlEPTB;OD60NFAxOiEQvF2=	MWrTRW5ITVJ?
NB14	M1;yUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3PZcGlEPTB;OD62N\|E{OyEQvF2=	MnnBV2FPT0WU
HD-MY-Z	NITJXldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MofCTWM2OD16Lk[zO\|Q3KM7:TR?=	M{LyW3NCVkeHUh?=
TE-10	NETXOXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFTRVmZKSzVyPUiuO\|Y{PTNizszN	MYLTRW5ITVJ?
LC-1F	NFfZdWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYDYVpBPUUN3ME25MlExQDN2IN88US=>	M{n6ZnNCVkeHUh?=
OS-RC-2	M1ywN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2rHZ2lEPTB;OT6xNVI1OyEQvF2=	NH\YN41USU6JRWK=
NCI-SNU-16	NUiyVGVwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{n4b2lEPTB;OT6yNVAzPiEQvF2=	M2m2UnNCVkeHUh?=
SHP-77	NV65OWd7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGTGV5RKSzVyPUmuO\|E3PjJizszN	M{WydHNCVkeHUh?=
A4-Fuk	NHfSfmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1TGbWlEPTB;OT63OVYyKM7:TR?=	M4PZbnNCVkeHUh?=
NB6	NFHWU5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGHvVZlKSzVyPUmuO\|YxOjlizszN	NUX0V41mW0GQR1XS
JiyoyeP-2003	NFjh[VZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{H2PGlEPTB;MUCuOFc1PSEQvF2=	NEHje\|BUSU6JRWK=
DMS-114	MmTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlH0TWM2OD1zMD61OFQyKM7:TR?=	Mle0V2FPT0WU
NB7	MkiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1PtVmlEPTB;MUCuO\|UzPiEQvF2=	M3faXHNCVkeHUh?=
NCI-H747	NV72T4ZTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIPlUnpKSzVyPUGxMlEzOTZizszN	NHHaeXJUSU6JRWK=
HH	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{m3bWlEPTB;MUGuN\|g4PiEQvF2=	NIDIWYVUSU6JRWK=
EW-18	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mmi4TWM2OD1zMT65NFQ1KM7:TR?=	NITQT3hUSU6JRWK=
CHP-126	MoP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVLYWGxtUUN3ME2xNU46PzN6IN88US=>	MlznV2FPT0WU
NTERA-S-cl-D1	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH7rUIlKSzVyPUGyMlAzPzhizszN	NYq2WHRsW0GQR1XS
DEL	MoPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUX0fVFxUUN3ME2xNk4xQTh3IN88US=>	MlK5V2FPT0WU
LU-139	NIjCfYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXvJR\|UxRTF{LkW0NVMh\|ryP	MUDTRW5ITVJ?
P30-OHK	M3z0PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoLtTWM2OD1zMj61OFc6KM7:TR?=	M4DmTXNCVkeHUh?=
NCI-H1522	M4[zS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2rWTWlEPTB;MUKuO\|Q3KM7:TR?=	M1\HZnNCVkeHUh?=
NCI-H1299	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NULR[4c1UUN3ME2xN{4zQTFzIN88US=>	M17UZ3NCVkeHUh?=
UACC-257	NUD1c5Y6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUX2cppXUUN3ME2xN{42OTJ4IN88US=>	MXHTRW5ITVJ?
Calu-6	M2fQS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVLWWpdZUUN3ME2xN{43ODR4IN88US=>	NFzV[XhUSU6JRWK=
NCI-H1882	Ml\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTF\|Lki1OVUh\|ryP	Ml\PV2FPT0WU
BB30-HNC	NEO5O2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV7JR\|UxRTF2LkC2NFkh\|ryP	NGrDUWRUSU6JRWK=
ES1	NHnJTWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MY\JR\|UxRTF2LkG1OVEh\|ryP	NYDoXZd2W0GQR1XS
NCI-H1694	NUPNT5ZxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3vUfWlEPTB;MUSuOFgyOSEQvF2=	NFHoUlZUSU6JRWK=
IST-SL1	NYXE[oVOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIrwfFRKSzVyPUG0Mlk3OTZizszN	Ml:1V2FPT0WU
ECC4	NIPxXlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnexTWM2OD1zNT6wOVU5KM7:TR?=	Ml21V2FPT0WU
MDA-MB-134-VI	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnrvTWM2OD1zNT60NVMyKM7:TR?=	M{TCN3NCVkeHUh?=
SCH	NHvseYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFPkc\|VKSzVyPUG1MlQ4OjhizszN	NHvkeYNUSU6JRWK=
SK-N-FI	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWft[olXUUN3ME2xOU43PTN2IN88US=>	MknMV2FPT0WU
HDLM-2	NXjuUIhTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlLsTWM2OD1zNj6wO\|E1KM7:TR?=	NIfnZpNUSU6JRWK=
Ramos-2G6-4C10	NY[4ZolzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVv5bIZ2UUN3ME2xOk4yOjl5IN88US=>	NYf2O\|Y4W0GQR1XS
EW-24	NWTyPJpCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn\FTWM2OD1zNj6xOlYyKM7:TR?=	NWj3W5RmW0GQR1XS
NCI-H2141	NGTpcVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW\JR\|UxRTF4LkG4PUDPxE1?	NXTWfocxW0GQR1XS
LC4-1	NFrhbIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIrwd5BKSzVyPUG2MlYyOTlizszN	MVvTRW5ITVJ?
HT-144	NFzBUXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTKWIVOUUN3ME2xO{4xODZizszN	NVvZUFhmW0GQR1XS
SK-MEL-1	NYe0RlJtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3niSGlEPTB;MUeuNFA4OiEQvF2=	M1TWd3NCVkeHUh?=
SCC-15	NWDwWYxmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUewbYI4UUN3ME2xO{4yPjN6IN88US=>	M3jtfnNCVkeHUh?=
C8166	NEXCZYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVjJR\|UxRTF5Lk[4N\|Mh\|ryP	NXnn[mRGW0GQR1XS
GOTO	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnO2TWM2OD1zNz64N\|Q1KM7:TR?=	NXzlbHFxW0GQR1XS
COR-L279	MmrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV7PWYJwUUN3ME2xPE4yOzZ{IN88US=>	MYLTRW5ITVJ?
K-562	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYS0SolyUUN3ME2xPE44OTR\|IN88US=>	M1TsZnNCVkeHUh?=
ES3	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYXJR\|UxRTF6LkiwOFEh\|ryP	MkDSV2FPT0WU
LU-165	NGXESYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NITHPFZKSzVyPUG5MlcxODhizszN	NY[1XlhNW0GQR1XS
KM-H2	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXrJR\|UxRTJyLkOxPFQh\|ryP	M3T6bXNCVkeHUh?=
RL	NHzuWWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVH4Wm5wUUN3ME2yNE46Pjl{IN88US=>	MX7TRW5ITVJ?
EW-3	NYTvZoxbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVfUT4ZJUUN3ME2yNU4yQDh7IN88US=>	MlrGV2FPT0WU
A101D	NH\NXZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MorOTWM2OD1{MT6zO\|UzKM7:TR?=	NXj1SI9pW0GQR1XS
HUTU-80	NHTUfXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoPITWM2OD1{MT6zPVQ3KM7:TR?=	NH3yb4FUSU6JRWK=
NCI-H23	NXzLfVZyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmDSTWM2OD1{MT6zPVkzKM7:TR?=	MXjTRW5ITVJ?
PF-382	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4q3WWlEPTB;MkGuOFQxOyEQvF2=	M4Xzd3NCVkeHUh?=
LB373-MEL-D	NUP4VohiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M16wOmlEPTB;MkGuOVYyPSEQvF2=	M1X0R3NCVkeHUh?=
TE-8	MnnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUTRem5zUUN3ME2yNU43Ozl2IN88US=>	MVLTRW5ITVJ?
TE-9	Mmf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3:3OmlEPTB;MkGuPFUyOyEQvF2=	MnzvV2FPT0WU
Daudi	MnTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEj6fpJKSzVyPUKxMlk{ODRizszN	NYLYc\|l[W0GQR1XS
D-542MG	NIGyWIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo\FTWM2OD1{Mj6wNlU3KM7:TR?=	NUjRS481W0GQR1XS
U-698-M	NFXvfGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NI\tZ3VKSzVyPUKyMlQ3ODNizszN	MmraV2FPT0WU
ES6	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWnWeIhMUUN3ME2yNk44OzZ4IN88US=>	NVXTPZFCW0GQR1XS
DU-4475	NUDPb3VYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXXWWVFIUUN3ME2yN{45QDl5IN88US=>	NVnPU4NHW0GQR1XS
ECC12	NWXiUnVET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWHJR\|UxRTJ2LkK4NFMh\|ryP	M1nTOHNCVkeHUh?=
C2BBe1	NF:yWnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTJ2LkOyN\|kh\|ryP	NHy5[VBUSU6JRWK=
IST-SL2	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH;3SG5KSzVyPUK0MlQ{PjJizszN	NEnNbWVUSU6JRWK=
DJM-1	NU\vUnpYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFn0bJRKSzVyPUK0MlUzOjFizszN	MlzBV2FPT0WU
DMS-153	MkO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVPJR\|UxRTJ2Lki2NVQh\|ryP	MU\TRW5ITVJ?
NB13	NV;FPJJKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1;vS2lEPTB;MkWuNFI3PSEQvF2=	MVzTRW5ITVJ?
SK-N-DZ	NWHEVYFyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYPJR\|UxRTJ4LkO0NVQh\|ryP	NWf1RXRKW0GQR1XS
COR-L88	M4S0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUnJR\|UxRTJ4LkW3PVYh\|ryP	M3nUWHNCVkeHUh?=
LU-65	M1KyTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1nVRmlEPTB;Mk[uPFU{PSEQvF2=	Mn;lV2FPT0WU
TGBC1TKB	M{HMNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnvmTWM2OD1{Nj65PFI5KM7:TR?=	NGm0b2lUSU6JRWK=
THP-1	NFnzVFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmnFTWM2OD1{Nz6yNVQyKM7:TR?=	NYPkN4VRW0GQR1XS
ONS-76	MkDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXfJR\|UxRTJ5LkOzNkDPxE1?	NH\sNpVUSU6JRWK=
LC-2-ad	M4jUdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX3Q[YliUUN3ME2yO{43OjNzIN88US=>	NWGxO2w{W0GQR1XS
EW-13	Ml\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRTJ7LkG3OFYh\|ryP	M3[zb3NCVkeHUh?=
MS-1	MorpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4LFc2lEPTB;M{CuO\|I4QCEQvF2=	MV3TRW5ITVJ?
NCI-H2227	Mn;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkHwTWM2OD1\|MD65PFA3KM7:TR?=	NWrvPVlSW0GQR1XS
LXF-289	M{nCeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MULJR\|UxRTNzLkS0PVIh\|ryP	NIXxb2JUSU6JRWK=
MC116	NWfUcXJVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnG5TWM2OD1\|Mj6wPFI3KM7:TR?=	MUfTRW5ITVJ?
EVSA-T	MnSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUTJR\|UxRTN{LkK1PFUh\|ryP	M2nnTHNCVkeHUh?=
CTB-1	NG\T[FZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWfJR\|UxRTN\|LkGxNFEh\|ryP	M1PyOnNCVkeHUh?=
COLO-320-HSR	NXLqOY9FT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{jtRmlEPTB;M{OuNVYxOyEQvF2=	MVjTRW5ITVJ?
NCI-H2196	Mmq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4rRcmlEPTB;M{OuNlU2PyEQvF2=	MnW2V2FPT0WU
LB2241-RCC	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4n2bWlEPTB;M{OuN\|E{PSEQvF2=	M4PNWXNCVkeHUh?=
LS-513	MkjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3WxWWlEPTB;M{OuPFY{QCEQvF2=	Ml;0V2FPT0WU
LP-1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmmwTWM2OD1\|Mz65PVU3KM7:TR?=	Ml7HV2FPT0WU
A253	NFjTd5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEezcZpKSzVyPUO0MlIzQTZizszN	MVXTRW5ITVJ?
SK-MM-2	NGPadGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW\JR\|UxRTN2Lkm0OVEh\|ryP	MnHZV2FPT0WU
NCI-H1963	MkLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWTJR\|UxRTN3LkOwO\|Ih\|ryP	MXHTRW5ITVJ?
MMAC-SF	MlvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIq1R3NKSzVyPUO1Mlg4QDVizszN	NVrNdINjW0GQR1XS
LB831-BLC	NF;WeGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEP2TZpKSzVyPUO2MlA3PTRizszN	MX3TRW5ITVJ?
WSU-NHL	M{fuSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVTJR\|UxRTN4LkG2OEDPxE1?	NFnvOlFUSU6JRWK=
CESS	NVPiXW5bT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHXUdm1KSzVyPUO2MlI5PDhizszN	MmLMV2FPT0WU
NEC8	NYnK[WNLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFXmVHhKSzVyPUO2MlU5OzVizszN	M{\NW3NCVkeHUh?=
KNS-42	NFfZd\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2L3UWlEPTB;M{euNVI{PyEQvF2=	M1niTXNCVkeHUh?=
MHH-CALL-2	NELpUFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY\4UHBLUUN3ME2zO{4yQDJzIN88US=>	NFzIfG1USU6JRWK=
K5	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2PWWmlEPTB;M{iuOFMh\|ryP	NXO4XpY4W0GQR1XS
CP66-MEL	NFXUXphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV\jVHVUUUN3ME2zPU4xPzN\|IN88US=>	NHjWSGlUSU6JRWK=
OPM-2	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmKyTWM2OD1\|OT64OFMzKM7:TR?=	M{HPbHNCVkeHUh?=
IST-MES1	NH;WZnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHLuWXRKSzVyPUSwMlMxQTZizszN	MlfuV2FPT0WU
EC-GI-10	NGHGZpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVzJR\|UxRTRzLkW4NFUh\|ryP	NV;0VVVCW0GQR1XS
CTV-1	M{HnZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF3JVnFKSzVyPUSyMlg1ODZizszN	NEm0U29USU6JRWK=
DG-75	M3rzNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVLJR\|UxRTR\|Lke1PVUh\|ryP	NYHpVZpUW0GQR1XS
KNS-81-FD	MoHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVnJR\|UxRTR3LkSwOVgh\|ryP	M2K5NXNCVkeHUh?=
NCI-H82	NEfK[ZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmLPTWM2OD12NT61O\|U5KM7:TR?=	MlvTV2FPT0WU
RPMI-8866	NFO1RW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX:wZpRnUUN3ME20Ok4yQDd\|IN88US=>	NYLtdo8{W0GQR1XS
ACN	MnHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnjjTWM2OD12Nj60N\|Qh\|ryP	NGTvWWtUSU6JRWK=
NCI-H1395	Mnr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF;kRYhKSzVyPUS2MlQ4PTZizszN	NWLteI42W0GQR1XS
NCI-H209	MkTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVztVnozUUN3ME20O{4yPDB3IN88US=>	MonUV2FPT0WU
TGW	NVnpSVBuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY\JR\|UxRTR7LkC3PVEh\|ryP	NYP1NYVPW0GQR1XS
NCI-H748	NWfQUFMyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{nrUmlEPTB;NEmuOFc2OyEQvF2=	NFTMfoZUSU6JRWK=
EKVX	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV;JR\|UxRTR7Lk[2Nlgh\|ryP	M1:5W3NCVkeHUh?=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ

Methods	Test Index	PMID
Western blot	LC3-I / LC-3II / ATG5; PubMed: 23392173 Cell Death Dis Sorafenib induces the conversion of LC3 in a dose-dependent manner. PLC5, Hep3B, SK-Hep1 and HepG2 were exposed to sorafenib at the indicated doses for 16 h and the expression levels of LC3-II were analyzed by western blot. p-STAT3 / STAT3 / Mcl-1; PubMed: 23392173 Cell Death Dis Effects of sorafenib on STAT3-related proteins in HCC cells. The cells were treated with sorafenib at the indicated dose for 16 h. β-catenin / Survivin / Mcl-1 / PTMA; PubMed: 26517516 Oncotarget Co-inhibition of β-catenin and PTMA by sorafenib in HCC cells. Cell lines indicated on top were treated or not with 10 μM sorafenib for 24 hrs and processed for immuno-blotting. IC50 values (the concentration of sorafenib that inhibits 50% of cell growth) for each cell line are indicated below the panels. pERK / ERK; PubMed: 22286758 Oncogene Western blot analysis of p-ERK (T202/Y204) and ERK at indicated time points in HCT116 cells treated with 20 μmol/L sorafenib. p-PKM2(y105) / PMK2 / Caspase-9; PubMed: 26959741 Oncotarget Sorafenib downregulates the p-PKM2 (Y105) at the indicated doses after treatment for 24 h. RET(pY1016) / VEGFR2(pY1214) / MEK1(pT292) / ERK(pY204); PubMed: 22941289 Acta Pharmacol Sin Sorafenib affected the phosphorylation of receptor tyrosine kinase RET and VEGFR2, as well as MEK/ERK kinases signaling cascades in three cell lines. Three cell lines were treated by sorafenib with two concentration gradients, 1 and 5 μmol/L/L, and then collected after 2, 4, and 8 h, cells without sorafenib treatment were as the controls (0 h). Total proteins were extracted and quantified to be used in Western blot assays. (A) Sorafenib inhibited RET and VEGFR2 phosphorylation dose-dependently while activated MEK and ERK phosphorylation in A549 cells. (B) Sorafenib also inhibited RET and VEGFR2 phosphorylation, and slightly activated MEK and ERK phosphorylation in HeLa cells. (C) Sorafenib activated the phosphorylation of RET, VEGFR2, and MEK, but inhibited ERK phosphorylation in HepG2 cells. Cyclin D1; PubMed: 26039995 Proc Natl Acad Sci U S A Dose-escalation effects of sorafenib or SC-1 for 24 h on STAT3-related proteins in HSC-T6 and LX2 cells.	23392173 26517516 22286758 26959741 22941289 26039995
Growth inhibition assay	Cell viability; PubMed: 26039995 Proc Natl Acad Sci U S A Dose-escalation and time-dependent effects of sorafenib for 24 or 48 h on cell viability in HSC-T6, LX2, and mouse primary HSCs. Circles, mean; bars, SE (n = 3).	26039995
Immunofluorescence	p65; PubMed: 22286758 Oncogene HCT116 cells were treated with 20 μmol/L sorafenib or 10 ng/mL TNF-α for 3 hours then fixed. Immunofluorescence was carried out as described in the Materials and Methods for p65 (green) and DAPI (blue). Representative pictures (400×) are shown. cytochrome c; PubMed: 22278289 Cell Death Dis Immunoflourescent staining and quantification of mitochondrial membrane potential (appearing in red, mitotracker) and cytochrome c (appearing in green, FITC) in 22Rv1 and PC3 treated with 20 μM sorafenib for 24 h.	22286758 22278289
ELISA	TGF-beta / CD206; PubMed: 26158762 Oncotarget In Macrophage, TGF-β secretion and CD206 were confirmed by ELISA. Caspase-9 / Caspase-3; PubMed: 30923462 Cancer Cell Int Caspase-9 and caspase-3 activities were measured via ELISA assay. FCCP, an activator of mitophagy, was added into the medium of sorafenib-treated cells to activate mitophagy. Adenovirus-loaded LATS2 (Ad-LATS2) was transfected into HepG2 cells in the presence of sorafenib. *p < 0.05 vs. control group; #p < 0.05 vs. Sorafenib + Ad-cont group; #p < 0.05 vs. Sorafenib + Ad-LATS2 group.	26158762 30923462

体内試験

Oral administration of Sorafenib (~60 mg/kg) demonstrates broad spectrum, dose-dependent anti-tumor activity against a variety of human tumor xenograft models including MDA-MB-231, Colo-205, HT-29, DLD-1, NCI-H460, and A549, with no evidence of toxicity. In association with the anti-tumor efficacy, Sorafenib treatment potently inhibits MEK 1/2 phosphorylation and pERK 1/2 levels in HT-29 and MDA-MB-231 xenografts but not in Colo-205 xenografts, and significantly suppresses tumor microvessel area (MVA) and microvessel density (MVD) in MDA MB-231, HT-29 and Colo-205 tumor xenografts. ^[1] Sorafenib treatment produces dose-dependent growth inhibition of PLC/PRF/5 tumor xenografts in SCID mice with TGIs of 49% and 78% at 10 mg/kg and 30 mg/kg, respectively, consistent with the inhibition of ERK and eIF4E phosphorylation, reduction of the microvessel area, and induction of tumor cell apoptosis. ^[2] Sorafenib sensitizes bax^-/- cells to TRAIL in a dose-dependent manner, through a mechanism involving down-regulating NF-κB mediated Mcl-1 and cIAP2 expression. Combining Sorafenib (30-60 mg/kg) with TRAIL (5 mg/kg) show dramatic efficacy in TRAIL-resistant HCT116 bax^-/- and HT29 tumor xenografts. ^[3]

お薦めの試験操作（参考用のみ）

キナーゼ試験： ^[1]	- 合併 Biochemical assays: Recombinant baculoviruses expressing Raf-1 (residues 305–648) and B-Raf (residues 409–765) are purified as fusion proteins. Full-length human MEK-1 is generated by PCR and purified as a fusion protein from Escherichia coli lysates. Sorafenib tosylate is added to a mixture of Raf-1 (80 ng), or B-Raf (80 ng) with MEK-1 (1 μg) in assay buffer [20 mM Tris (pH 8.2), 100 mM NaCl, 5 mM MgCl₂, and 0.15% β-mercaptoethanol] at a final concentration of 1% DMSO. The Raf kinase assay (final volume of 50 μL) is initiated by adding 25 μL of 10 μM γ[³³P]ATP (400 Ci/mol) and incubated at 32 °C for 25 minutes. Phosphorylated MEK-1 is harvested by filtration onto a phosphocellulose mat, and 1% phosphoric acid is used to wash away unbound radioactivity. After drying by microwave heating, a β-plate counter is used to quantify filter-bound radioactivity. Human VEGFR2 (KDR) kinase domain is expressed and purified from Sf9 lysates. Time-resolved fluorescence energy transfer assays for VEGFR2 are performed in 96-well opaque plates in the time-resolved fluorescence energy transfer format. Final reaction conditions are as follows: 1 to 10 μM ATP, 25 nM poly GT-biotin, 2 nM Europium-labeled phospho (p)-Tyr antibody (PY20), 10 nM APC, 1 to 7 nM cytoplasmic kinase domain in final concentrations of 1% DMSO, 50 mM HEPES (pH 7.5), 10 mM MgCl₂, 0.1 mM EDTA, 0.015% Brij-35, 0.1 mg/mL BSA, and 0.1% β-mercaptoethanol. Reaction volumes are 100 μL and are initiated by addition of enzyme. Plates are read at both 615 and 665 nM on a Perkin-Elmer VictorV Multilabel counter at ~1.5 to 2.0 hours after reaction initiation. Signal is calculated as a ratio: (665 nm/615 nM) × 10,000 for each well. For IC50 generation, Sorafenib tosylate is added before the enzyme initiation. A 50-fold stock plate is made with Sorafenib tosylate serially diluted 1:3 in a 50% DMSO/50% distilled water solution. Final Sorafenib tosylate concentrations range from 10 μM to 4.56 nM in 1% DMSO.
細胞試験： ^[1]	- 合併細胞株： MDA-MB-231, and HAoSMC 濃度： Dissolved in DMSO, final concentrations ~10 μM 反応時間： 72 hours 実験の流れ： Cells are exposed to increasing concentrations of Sorafenib tosylate for 72 hours. Cell number is quantitated using the Cell TiterGlo ATP Luminescent assay kit. This assay measures the number of viable cells per well by measurement of luminescent signal based on amount of cellular ATP. (参考用のみ)
動物試験： ^[1]	- 合併動物モデル： Female NCr-nu/nu mice implanted s.c. with MDA-MB-231, Colo-205, HT-29, H460, or A549 cells 製剤： Dissolved in Cremophor EL/ethanol (50:50) as 4-fold (4 × stock solution, and diluted to 1 × with water 投薬量： ~60 mg/kg 投与方法： Orally once daily (参考用のみ)

参考

溶解度 (25°C)

体外	DMSO	63 mg/mL (135.53 mM) warming
	Water	Insoluble
	Ethanol	Insoluble
体内	左から（NMPから）右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ): 5% DMSO+45% PEG 400+ddH2O 混合させたのち直ちに使用することを推奨します。	3mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報 Sorafenib SDFをダウンロードする

分子量	464.82
化学式	C₂₁H₁₆ClF₃N₄O₃
CAS No.	284461-73-0
保管	3年-20°C粉
保管	2 years-80°C in solvent
別名	BAY 43-9006
Smiles	CNC(=O)C1=CC(=CC=N1)OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2

便利ツール

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

質量

濃度

体積

分子量
=

×

×

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA（製品ページで利用可能な）。

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます：

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます：C1V1 = C2V2 ( 入力出力 )

C1

V1

C2

V2
×

=

×

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA（オンラインで利用できる）で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

連続希釈剤
初めの濃度：
稀釈倍数：

計算結果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください：

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

臨床試験 (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04000737	Not yet recruiting	Drug: YIV-906+Sorafenib\|Drug: Placebo+Sorafenib	Advanced Hepatocellular Carcinoma	Yiviva Inc.	August 15 2019	Phase 2
NCT03958669	Not yet recruiting	--	Hepatocellular Carcinoma\|Sorafenib	University Hospital Tuebingen\|German Federal Ministry of Education and Research	July 1 2019	--
NCT03764293	Not yet recruiting	Drug: SHR-1210\|Drug: Apatinib\|Drug: Sorafenib	Locally Advanced or Metastatic and Unresectable HCC	Jiangsu HengRui Medicine Co. Ltd.	January 2019	Phase 3
NCT03582618	Recruiting	Drug: Sorafenib\|Drug: CVM-1118	Hepatocellular Carcinoma\|Advanced Cancer	TaiRx Inc.	July 12 2018	Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

Rafシグナル伝達経路

相関Raf製品

LY3009120

LY03009120 is a potent pan-Raf inhibitor with IC50 of 44 nM, 31-47 nM, and 42 nM for A-raf, B-Raf, and C-Raf in A375 cells, respectively. Phase 1.
GDC-0994

GDC-0994 is a potent, orally available and highly selective ERK1/2 inhibitor with IC50 of 1.1 nM and 0.3 nM, respectively. Phase 1.
Ulixertinib (BVD-523)

Ulixertinib (BVD-523, VRT752271) is a potent and reversible ERK1/ERK2 inhibitor with IC50 of <0.3 nM for ERK2. Phase 1.
Vemurafenib (PLX4032)

Vemurafenib (PLX4032, RG7204) is a novel and potent inhibitor of B-Raf^V600E with IC50 of 31 nM in cell-free assay. 10-fold selective for B-Raf^V600E over wild-type B-Raf in enzymatic assays and the cellular selectivity can exceed 100-fold.

Features:A novel and potent inhibitor of the B-RAF^V600E oncoprotein.
Dabrafenib (GSK2118436)

Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.8 nM in cell-free assays, with 4- and 6-fold less potency against B-Raf(wt) and c-Raf, respectively.
Sorafenib Tosylate

Sorafenib Tosylate is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.
PLX-4720

PLX4720 is a potent and selective inhibitor of B-Raf^V600E with IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), 10-fold selectivity for B-RafV600E than wild-type B-Raf.

研究分野別

製品類型

Sorafenib

文献中Selleckの製品使用例(206)

製品安全説明書

Raf阻害剤の選択性比較

生物活性

お薦めの試験操作（参考用のみ）

参考

溶解度 (25°C)

化学情報 Sorafenib SDFをダウンロードする

便利ツール

モル濃度計算器

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

希釈計算器

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

連続希釈計算器方程式

連続希釈剤

計算結果

分子量计算器

総分子量：g/mol

モル濃度計算器

臨床試験 (data from https://clinicaltrials.gov, updated on 2019-10-14)

技術サポート

Rafシグナル伝達経路

相関Raf製品